"Though Ambardar believes RSV awareness is on the rise, she says the existing lack of patient education-coupled with COVID- and flu-induced vaccine fatigue-may account for minimal interest in the trio of new RSV vaccines for people 60 and older."
"As recently as 18 months ago, no RSV vaccine existed. The Food and Drug Administration (FDA) approved the nation's first RSV vaccine, GSK's Arexvy, on May 3, 2023. In a statement that day, Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, deemed the occasion 'an important public health achievement to prevent a disease which can be life-threatening.'"
"Vaccine uptake may not be much better during the 2024-25 respiratory virus season. Fewer than two in five (38%) eligible recipients plan to get an RSV vaccine, according to a survey conducted in August by the National Foundation for Infectious Diseases (NFID)."
[
Collection
]
[
|
...
]